BY Christopher Karlsson
-
Novo Nordisk Foundation secures BII for another 10 years – supported by another large billion-kroner grant
The brand-new billion-kroner give will certainly make it possible for the Bioinnovation Institute (BII) to broaden its tasks right into brand-new critical locations and locations a…
-
Gubra adds another face to the management team: Creates new position with focus on acquisitions
To name a few points, the brand-new supervisor will certainly concentrate on licensing arrangements and procurements that can enhance Gubra’s biotech pipe.
-
US company unveils candidate for Gubra partnership
As an outcome of the choice, Gubra is readied to get a landmark repayment of $4 million, equal to roughly DKK 26 million.
-
Novo Nordisk starts phase 1 trial of new diabetes drug
The test will certainly examine whether the medicine can decrease high blood sugar level and if it is secure and well endured.
-
Gubra keeps details of new Swedish collaboration under wraps
Danish biotech Gubra decreases to reveal monetary regards to brand-new offer with Swedish company Camurus.
-
Novo Nordisk seals acquisition of Akero Therapeutics
The Danish pharmaceutical business has actually formerly mentioned that the procurement is anticipated to have an adverse influence on following year’s development in operati…
-
Zealand Pharma to quintuple research costs as part of new strategy
The Danish business is likewise readied to obtain a significant settlement following year as an outcome of its contract with Swiss business Roche, according to CFO.
-
Another change to Leo Pharma’s management: Strategy manager leaves for Swedish company
Leo Pharma reveals that, as an outcome of the separation, the firm has actually designated Gustav Gøbel Nielsen as its brand-new vice head of state of method
-
Bioinnovation Institute appoints new director with international focus
The brand-new chief executive officer changes Bobby Soni, that left his setting as primary global policeman back in the springtime.
-
Novo Nordisk seals acquisition of Akero Therapeutics
The Danish pharmaceutical company has previously stated that the acquisition is expected to have a negative impact on next year’s growth in operating profit.
